SCHEMBL7120830

SCHEMBL7120830

Cc1cccc(-c2csc(N)n2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.65
MEN1 O00255 8/20 0.65
KMT2A Q03164 8/20 0.65
RAB9A P51151 7/20 0.65
MAPT P10636 5/20 0.65
KDM4E B2RXH2 3/20 0.65
HPGD P15428 3/20 0.65
HK1 P19367 1/20 0.65
HKDC1 Q2TB90 1/20 0.65
LTA4H P09960 2/20 0.64
ATP4A P20648 2/20 0.61
ATP4B P51164 2/20 0.61
TSHR P16473 1/20 0.58
RECQL P46063 1/20 0.58
NPC1 O15118 5/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
NFKB1 P19838 2/20 0.58
NFKB2 Q00653 2/20 0.58
RELA Q04206 2/20 0.58
LMNA P02545 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14315461 0.87 LTA4H (0.55) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL8257849 0.84 RECQL (0.70) ALDH1A1RAB9AMAPTKDM4EHPGD
SCHEMBL3767170 0.82 ATP4A (0.57) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL30087395 0.82 ATP4A (0.57) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL4636395 0.81 TSHR (0.72) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL22290627 0.81 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL27985361 0.81 LTA4H (0.54) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL7238636 0.81 RAB9A (0.70) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL9454811 0.81 ATP4A (0.56) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL30118263 0.80 MEN1 (0.64) ALDH1A1MEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0006368-B1 4-PHENYL-THIAZOLYL-2-OXAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF ASTHMA PIERRE FABRE S.A. (FR) 1981-11-18 EP claimed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 US disclosed
CN-115466229-B Para-amidobenzenesulfonyl compound and application thereof 上海中医药大学 2025-01-24 CN disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
CN-115466229-A P-acylamino benzenesulfonyl compound and application thereof 上海中医药大学 2022-12-13 CN disclosed
US-11497752-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2022-11-15 US disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
CN-111116575-B 5-fluoro-2, 4-pyrimidinediamine compound and preparation and application thereof 浙江工业大学 2021-06-15 CN disclosed
US-7968577-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-06-28 US disclosed
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
US-7645799-B2 Substituted biaryl compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-12 US disclosed
US-7544808-B2 Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-09 US disclosed
US-20090062287-A1 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-05 US disclosed
US-7459564-B2 Substituted biaryl compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-02 US disclosed
WO-2008057862-A2 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-15 WO disclosed
US-20030134859-A1 PPAR-gamma modulator SANKYO COMPANY, LIMITED (JP) 2003-07-17 US disclosed
EP-1277729-A1 PPAR (GAMMA) MODULATORS Sankyo Company, Limited (JP) 2003-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063051-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NFKB2, NFKBIA ALDH1A1 4179/4885MEN1 3339/4885KMT2A 2852/4885
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885MEN1 1366/4885KMT2A 792/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB ALDH1A1 2571/4885MEN1 1366/4885KMT2A 792/4885
US-20030134859-A1 PPAR-gamma modulator PPARG, PPARA, PPARD ALDH1A1 583/4885MEN1 4865/4885KMT2A 3291/4885
US-11497752-B2 Compounds and uses thereof VHL, CLN6, TFEB ALDH1A1 2571/4885MEN1 1366/4885KMT2A 792/4885
US-20090062287-A1 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS TFPI, F3, F12 ALDH1A1 4002/4885MEN1 1713/4885KMT2A 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.